GlassScriptPhysician profile
Eduard Kraychik
NPI 1689611196
$13,620.68
in general payments reported to CMS, 2019-2025
15 companies · $708 in 2025
The $708 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $623 · 2021: $44.23 · 2022: $126 · 2023: $225 · 2024: $675 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466 · Consulting Fee: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.59 |
| Consulting Fee | $143.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $11,224.60 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $578.10 | 2019-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $495.62 | 2023-2025 | Auvelity |
| Abbvie INC. | $415.17 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $143.00 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.34 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $141.85 | 2023 | Ozempic |
| Ethicon US, LLC | $97.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.16 | 2019-2025 | Trintellix |
| Pfizer INC. | $79.83 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $78.00 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $45.97 | 2019-2024 | Austedo Xr |
| Lundbeck LLC | $42.33 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $36.64 | 2019-2020 | |
| Allergan, INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduard Kraychik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.